Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial
Clinical Trial
[키워드] 1-year follow-up results
administration
adverse event
analyzed
antibody
benefit
Biomarkers
Cell
China
clinical trial
cohort study
consequence
COVID-19
COVID-19 patients
double-blind
Effectiveness
enrolled
evaluate
Follow-up
follow-up time
foundation
group
High-resolution CT
Human
in both group
incidence
Innovation
interval
Lung function
lung lesion
Major
median
mesenchymal stem cell
Mesenchymal stem cells treatment
MSC
natural
Other
outcome
outcomes
Patient
phase 2 trial
Placebo
placebo-controlled trial
plasma
positive
primary endpoint
Program
proportion
Randomized
RCT
RCT.
recorded
recruited
reduced
Registered
reported
Science
severe COVID-19
stem cell
Symptom
technology
the placebo group
Treatment
treatment for COVID-19
Trial
tumor marker
two groups
UC-MSC
umbilical
Volume
walking distance
[DOI] 10.1016/j.ebiom.2021.103789 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1016/j.ebiom.2021.103789 PMC 바로가기 [Article Type] Clinical Trial